CSIMarket
 


Zeo Scientifix Inc   (BPSR)
Other Ticker:  
 
 

BPSR's Income from Cont. Operations Growth by Quarter and Year

Zeo Scientifix Inc 's Income from Cont. Operations results by quarter and year




BPSR Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter October - -3.02 -0.96 -5.16
III Quarter July - -2.73 -1.41 -5.26
II Quarter April - -1.46 -2.24 -1.46
I Quarter January -2.29 -1.69 -8.15 -0.70
FY   -2.29 -8.90 -12.76 -12.58



BPSR Income from Cont. Operations first quarter 2023 Y/Y Growth Comment
Zeo Scientifix Inc in the first quarter 2023 recorded loss from continued operations of $ -2.29 millions.

According to the results reported in the first quarter 2023, Zeo Scientifix Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Zeo Scientifix Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter 2023.




BPSR Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter October - - - -
III Quarter July - - - -
II Quarter April - - - -
I Quarter January - - - -
FY   - - - -

Financial Statements
Zeo Scientifix Inc 's first quarter 2023 Income from Cont. Operations $ -2.29 millions BPSR's Income Statement
Zeo Scientifix Inc 's first quarter 2022 Income from Cont. Operations $ -1.69 millions Quarterly BPSR's Income Statement
New: More BPSR's historic Income from Cont. Operations Growth >>


BPSR Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter October - - - -
III Quarter July - - - -
II Quarter April - - - -
I Quarter January - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Zeo Scientifix Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BPSR's I. Quarter Q/Q Income from Cont. Operations Comment
Although Zeo Scientifix Inc in the I. Quarter 2023 showed loss from continued operations of $ -2.29 millions, it should be mentioned, that current results show improvement compare to the -3.02 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry Zeo Scientifix Inc achieved highest sequential Income from Cont. Operations growth. While Zeo Scientifix Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BPSR's I. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Zeo Scientifix Inc in the I. Quarter 2023 revealed loss from continued operations of $ -2.29 millions, some analyst point out, that this show slight up side in contrast to the -3.02 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry Zeo Scientifix Inc achieved highest sequential Income from Cont. Operations growth. While Zeo Scientifix Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Zeo Scientifix Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jan 31 2023)
12 Months Ending
(Oct 31 2022)
12 Months Ending
(Jul 31 2022)
12 Months Ending
(Apr 30 2022)
12 Months Ending
(Jan 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -9.49 $ -8.90 $ -6.84 $ -5.52 $ -6.30
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Zeo Scientifix Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -9 millions in the Jan 31 2023 period.
The results are worsening as the cumulative loss from continued operations is getting bigger from $ -8.9 millions for the period from Oct 31 2022 to Jan 31 2022 and $ -12.75656 millions from the TTM period ending Jan 31 2022.

Zeo Scientifix Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Zeo Scientifix Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -9 millions in the Jan 31 2023 period.
The business is worsening as the cumulative loss from continued operations is getting bigger from $ -8.9 millions for the period from Oct 31 2022 to Jan 31 2022 and $ -12.75656 millions for the twelve months ending in the quarter a year ago.

Zeo Scientifix Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
BPSR's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for BPSR's Competitors
Income from Cont. Operations Growth for Zeo Scientifix Inc 's Suppliers
Income from Cont. Operations Growth for BPSR's Customers

You may also want to know
BPSR's Annual Growth Rates BPSR's Profitability Ratios BPSR's Asset Turnover Ratio BPSR's Dividend Growth
BPSR's Roe BPSR's Valuation Ratios BPSR's Financial Strength Ratios BPSR's Dividend Payout Ratio
BPSR's Roa BPSR's Inventory Turnover Ratio BPSR's Growth Rates BPSR's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Jan 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jan 31 2023
Agilent Technologies inc 24.38%$ 24.382 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com